{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:05:20Z","timestamp":1768435520979,"version":"3.49.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,16]]},"DOI":"10.7759\/cureus.67007","type":"journal-article","created":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T15:12:27Z","timestamp":1723821147000},"source":"Crossref","is-referenced-by-count":3,"title":["The Efficacy of Renal Denervation in Treating Resistant Hypertension: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Gibran A","family":"Azeez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mounika","family":"Thirunagari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nazeefa","family":"Fatima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhinav","family":"Anand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aadi R","family":"Palvia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avneet","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sondos T","family":"Nassar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.05.074","article-title":"2017 ACC\/AHA blood pressure treatment guideline recommendations and cardiovascular risk","volume":"72","author":"Colantonio LD","year":"2018","unstructured":"Colantonio LD, Booth JN 3rd, Bress AP, et al.. 2017 ACC\/AHA blood pressure treatment guideline recommendations and cardiovascular risk. J Am Coll Cardiol. 2018, 72:1187-97. 10.1016\/j.jacc.2018.05.074","journal-title":"J Am Coll Cardiol"},{"key":"ref2","unstructured":"World Health Organization. Hypertension. (2023). Accessed: May 8, 2024: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hypertension."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.108.189141","article-title":"Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research","volume":"51","author":"Calhoun DA","year":"2008","unstructured":"Calhoun DA, Jones D, Textor S, et al.. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008, 51:1403-19. 10.1161\/HYPERTENSIONAHA.108.189141","journal-title":"Hypertension"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.90a.22046","article-title":"Resistant hypertension: a stepwise approach","volume":"90","author":"Yahr J","year":"2023","unstructured":"Yahr J, Thomas G, Calle J, Taliercio JJ. Resistant hypertension: a stepwise approach. Cleve Clin J Med. 2023, 90:115-25. 10.3949\/ccjm.90a.22046","journal-title":"Cleve Clin J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-050922-052605","article-title":"Management of resistant hypertension","volume":"75","author":"Lauder L","year":"2024","unstructured":"Lauder L, Mahfoud F, B\u00f6hm M. Management of resistant hypertension. Annu Rev Med. 2024, 75:443-57. 10.1146\/annurev-med-050922-052605","journal-title":"Annu Rev Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13050714","article-title":"The road to better management in resistant hypertension-diagnostic and therapeutic insights","volume":"13","author":"B\u0103dil\u0103 E","year":"2021","unstructured":"B\u0103dil\u0103 E, Japie C, Weiss E, Balahura AM, Barto\u0219 D, Scafa Udri\u0219te A. The road to better management in resistant hypertension-diagnostic and therapeutic insights. Pharmaceutics. 2021, 13:10.3390\/pharmaceutics13050714","journal-title":"Pharmaceutics"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2023.8555","article-title":"Management of resistant hypertension-an update","volume":"184","author":"Giacona JM","year":"2024","unstructured":"Giacona JM, Kositanurit W, Vongpatanasin W. Management of resistant hypertension-an update. JAMA Intern Med. 2024, 184:433-4. 10.1001\/jamainternmed.2023.8555","journal-title":"JAMA Intern Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002003.pub5","article-title":"Beta-blockers for hypertension","volume":"1","author":"Wiysonge CS","year":"2017","unstructured":"Wiysonge CS, Bradley HA, Volmink J, Mayosi BM, Opie LH. Beta-blockers for hypertension. Cochrane Database Syst Rev. 2017, 1:CD002003. 10.1002\/14651858.CD002003.pub5","journal-title":"Cochrane Database Syst Rev"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011499.pub3","article-title":"Renal denervation for resistant hypertension","volume":"11","author":"Pisano A","year":"2021","unstructured":"Pisano A, Iannone LF, Leo A, Russo E, Coppolino G, Bolignano D. Renal denervation for resistant hypertension. Cochrane Database Syst Rev. 2021, 11:CD011499. 10.1002\/14651858.CD011499.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.41598","article-title":"The implementation of renal denervation in the management of resistant hypertension despite use of multitherapy antihypertensives at maximally tolerated doses: a contemporary literature review","volume":"15","author":"Obi MF","year":"2023","unstructured":"Obi MF, Sharma M, Reinberg MA, N'Dandu Z, Hyun Joon C, Vega M. The implementation of renal denervation in the management of resistant hypertension despite use of multitherapy antihypertensives at maximally tolerated doses: a contemporary literature review. Cureus. 2023, 15:e41598. 10.7759\/cureus.41598","journal-title":"Cureus"},{"key":"ref11","article-title":"Renal denervation in the treatment of resistant hypertension","volume":"76","author":"Yap LB","year":"2021","unstructured":"Yap LB, Balachandran K. Renal denervation in the treatment of resistant hypertension. Med J Malaysia. 2021, 76:893-7.","journal-title":"Med J Malaysia"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2022.09.025","article-title":"The rise and fall and rise of renal\u00a0denervation","volume":"80","author":"Bhatt DL","year":"2022","unstructured":"Bhatt DL. The rise and fall and rise of renal\u00a0denervation. J Am Coll Cardiol. 2022, 80:1881-3. 10.1016\/j.jacc.2022.09.025","journal-title":"J Am Coll Cardiol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s41073-019-0064-8","article-title":"SANRA-a scale for the quality assessment of narrative review articles","volume":"4","author":"Baethge C","year":"2019","unstructured":"Baethge C, Goldbeck-Wood S, Mertens S. SANRA-a scale for the quality assessment of narrative review articles. Res Integr Peer Rev. 2019, 4:5. 10.1186\/s41073-019-0064-8","journal-title":"Res Integr Peer Rev"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea BJ","year":"2017","unstructured":"Shea BJ, Reeves BC, Wells G, et al.. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017, 358:j4008. 10.1136\/bmj.j4008","journal-title":"BMJ"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-011458","article-title":"Development of a critical appraisal tool to assess the quality of cross-sectional studies (AXIS)","volume":"6","author":"Downes MJ","year":"2016","unstructured":"Downes MJ, Brennan ML, Williams HC, Dean RS. Development of a critical appraisal tool to assess the quality of cross-sectional studies (AXIS). BMJ Open. 2016, 6:e011458. 10.1136\/bmjopen-2016-011458","journal-title":"BMJ Open"},{"key":"ref17","unstructured":"JBI. Critical appraisal tools. (2020). Accessed: June 24, 2024: https:\/\/jbi.global\/critical-appraisal-tools."},{"key":"ref18","unstructured":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. (2021). Accessed. June 24, 2024: https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp."},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref20","unstructured":"NIH. Study quality assessment tools. (2021). Accessed: June 24, 2024: https:\/\/www.nhlbi.nih.gov\/health-topics\/study-quality-assessment-tools."},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne JA","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, et al.. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016, 355:i4919. 10.1136\/bmj.i4919","journal-title":"BMJ"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1211199","article-title":"When blood pressure refuses to budge: exploring the complexity of resistant hypertension","volume":"10","author":"Champaneria MK","year":"2023","unstructured":"Champaneria MK, Patel RS, Oroszi TL. When blood pressure refuses to budge: exploring the complexity of resistant hypertension. Front Cardiovasc Med. 2023, 10:1211199. 10.3389\/fcvm.2023.1211199","journal-title":"Front Cardiovasc Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241612911","article-title":"Advances in the pathogenesis and treatment of resistant hypertension","volume":"24","author":"Dybiec J","year":"2023","unstructured":"Dybiec J, Krzemi\u0144ska J, Radzioch E, et al.. Advances in the pathogenesis and treatment of resistant hypertension. Int J Mol Sci. 2023, 24:10.3390\/ijms241612911","journal-title":"Int J Mol Sci"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2022.06.019","article-title":"Renal sympathetic denervation for hypertension","volume":"7","author":"Guber K","year":"2022","unstructured":"Guber K, Kirtane AJ. Renal sympathetic denervation for hypertension. Kidney Int Rep. 2022, 7:2129-40. 10.1016\/j.ekir.2022.06.019","journal-title":"Kidney Int Rep"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-021-01309-3","article-title":"Effect of renal denervation on long-term outcomes in patients with resistant hypertension","volume":"20","author":"Liang B","year":"2021","unstructured":"Liang B, Liang Y, Li R, Gu N. Effect of renal denervation on long-term outcomes in patients with resistant hypertension. Cardiovasc Diabetol. 2021, 20:117. 10.1186\/s12933-021-01309-3","journal-title":"Cardiovasc Diabetol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jimed.2021.05.006","article-title":"Endovascular denervation (EDN): from hypertension to non-hypertension diseases","volume":"4","author":"Pan T","year":"2021","unstructured":"Pan T, Zhang Q, Guo J. Endovascular denervation (EDN): from hypertension to non-hypertension diseases. J Interv Med. 2021, 4:130-5. 10.1016\/j.jimed.2021.05.006","journal-title":"J Interv Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.15420\/icr.2022.38","article-title":"Renal denervation: a practical guide for health professionals managing hypertension","volume":"18","author":"Schmieder R","year":"2023","unstructured":"Schmieder R, Burnier M, East C, Tsioufis K, Delaney S. Renal denervation: a practical guide for health professionals managing hypertension. Interv Cardiol. 2023, 18:e06. 10.15420\/icr.2022.38","journal-title":"Interv Cardiol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfad231","article-title":"Late outcomes of renal denervation are more favourable than early ones: facts or fancies?","volume":"16","author":"Persu A","year":"2023","unstructured":"Persu A, Stoenoiu MS, Maes F, Kreutz R, Mancia G, Kjeldsen SE. Late outcomes of renal denervation are more favourable than early ones: facts or fancies?. Clin Kidney J. 2023, 16:2357-64. 10.1093\/ckj\/sfad231","journal-title":"Clin Kidney J"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.15212\/CVIA.2023.0014","article-title":"Advances in renal denervation in the treatment of hypertension","volume":"7","author":"Xiong B","year":"2023","unstructured":"Xiong B, Chen S, Chen W, Yin Y, Ling Z. Advances in renal denervation in the treatment of hypertension. Cardiovasc Innov Appl. 2023, 7:26. 10.15212\/CVIA.2023.0014","journal-title":"Cardiovasc Innov Appl"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.carrev.2021.01.031","article-title":"Randomized blinded placebo-controlled trials of renal sympathetic denervation for hypertension: a meta-analysis","volume":"34","author":"Ahmad Y","year":"2022","unstructured":"Ahmad Y, Kane C, Arnold AD, et al.. Randomized blinded placebo-controlled trials of renal sympathetic denervation for hypertension: a meta-analysis. Cardiovasc Revasc Med. 2022, 34:112-8. 10.1016\/j.carrev.2021.01.031","journal-title":"Cardiovasc Revasc Med"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.26599\/1671-5411.2023.02.003","article-title":"Effect of renal denervation for patients with isolated systolic hypertension: a systematic review and meta-analysis","volume":"20","author":"Li L","year":"2023","unstructured":"Li L, Xiong YL, Tu B, Liu SY, Zhang ZH, Hu Z, Yao Y. Effect of renal denervation for patients with isolated systolic hypertension: a systematic review and meta-analysis. J Geriatr Cardiol. 2023, 20:121-9. 10.26599\/1671-5411.2023.02.003","journal-title":"J Geriatr Cardiol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000003727","article-title":"Renal denervation for uncontrolled hypertension: a systematic review and meta-analysis examining multiple subgroups","volume":"42","author":"Sharp AS","year":"2024","unstructured":"Sharp AS, Sanderson A, Hansell N, et al.. Renal denervation for uncontrolled hypertension: a systematic review and meta-analysis examining multiple subgroups. J Hypertens. 2024, 42:1133-44. 10.1097\/HJH.0000000000003727","journal-title":"J Hypertens"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10040782","article-title":"Renal denervation for uncontrolled and resistant hypertension: systematic review and network meta-analysis of randomized trials","volume":"10","author":"Silverwatch J","year":"2021","unstructured":"Silverwatch J, Marti KE, Phan MT, et al.. Renal denervation for uncontrolled and resistant hypertension: systematic review and network meta-analysis of randomized trials. J Clin Med. 2021, 10:10.3390\/jcm10040782","journal-title":"J Clin Med"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.4329\/wjr.v14.i7.238","article-title":"Catheter-based renal sympathetic nerve denervation on hypertension management outcomes","volume":"14","author":"Singh SP","year":"2022","unstructured":"Singh SP, Varghese KJ, Qureshi FM, Anderson MC, Foxworth J, Knuepfer MM. Catheter-based renal sympathetic nerve denervation on hypertension management outcomes. World J Radiol. 2022, 14:238-48. 10.4329\/wjr.v14.i7.238","journal-title":"World J Radiol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.hjc.2021.04.003","article-title":"Joint ESH excellence centers' national meeting on renal sympathetic denervation: a Greek experts' survey","volume":"62","author":"Doumas M","year":"2021","unstructured":"Doumas M, Andreadis E, Andronoglou M, et al.. Joint ESH excellence centers' national meeting on renal sympathetic denervation: a Greek experts' survey. Hellenic J Cardiol. 2021, 62:355-8. 10.1016\/j.hjc.2021.04.003","journal-title":"Hellenic J Cardiol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v9.i32.9970","article-title":"Computed tomography-guided chemical renal sympathetic nerve modulation in the treatment of resistant hypertension: a case report","volume":"9","author":"Luo G","year":"2021","unstructured":"Luo G, Zhu JJ, Yao M, Xie KY. Computed tomography-guided chemical renal sympathetic nerve modulation in the treatment of resistant hypertension: a case report. World J Clin Cases. 2021, 9:9970-6. 10.12998\/wjcc.v9.i32.9970","journal-title":"World J Clin Cases"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/6895993","article-title":"Insight on efficacy of renal artery denervation for refractory hypertension with chronic kidney diseases: a long-term follow-up of 24-hour ambulatory blood pressure","volume":"2022","author":"Cai H","year":"2022","unstructured":"Cai H, Fang Z, Lin R, Cai W, Han Y, Su J. Insight on efficacy of renal artery denervation for refractory hypertension with chronic kidney diseases: a long-term follow-up of 24-hour ambulatory blood pressure. J Interv Cardiol. 2022, 2022:6895993. 10.1155\/2022\/6895993","journal-title":"J Interv Cardiol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.022429","article-title":"Comparison of long-term outcomes for responders versus non-responders following renal denervation in resistant hypertension","volume":"10","author":"Fengler K","year":"2021","unstructured":"Fengler K, Reimann P, Rommel KP, et al.. Comparison of long-term outcomes for responders versus non-responders following renal denervation in resistant hypertension. J Am Heart Assoc. 2021, 10:e022429. 10.1161\/JAHA.121.022429","journal-title":"J Am Heart Assoc"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.3390\/medicina57070662","article-title":"Long-term effects of renal artery denervation","volume":"57","author":"Juknevi\u010dius V","year":"2021","unstructured":"Juknevi\u010dius V, Ber\u016bk\u0161tis A, Juknevi\u010dien\u0117 R, Jasi\u016bnas E, \u0160erpytis P, Laucevi\u010dius A. Long-term effects of renal artery denervation. Medicina (Kaunas). 2021, 57:10.3390\/medicina57070662","journal-title":"Medicina (Kaunas)"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2022.08.802","article-title":"Cardiovascular risk reduction after renal denervation according to time in therapeutic systolic blood pressure range","volume":"80","author":"Mahfoud F","year":"2022","unstructured":"Mahfoud F, Mancia G, Schmieder RE, et al.. Cardiovascular risk reduction after renal denervation according to time in therapeutic systolic blood pressure range. J Am Coll Cardiol. 2022, 80:1871-80. 10.1016\/j.jacc.2022.08.802","journal-title":"J Am Coll Cardiol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.4149\/BLL_2022_113","article-title":"Renal denervation in resistant hypertension treatment","volume":"123","author":"Orekhov AU","year":"2022","unstructured":"Orekhov AU, Sabitov YT, Karazhanova LK. Renal denervation in resistant hypertension treatment. Bratisl Lek Listy. 2022, 123:710-5. 10.4149\/BLL_2022_113","journal-title":"Bratisl Lek Listy"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.030767","article-title":"Twenty-four-month blood pressure results after renal denervation using endovascular ultrasound","volume":"12","author":"Rosch S","year":"2023","unstructured":"Rosch S, Rommel KP, Blazek S, et al.. Twenty-four-month blood pressure results after renal denervation using endovascular ultrasound. J Am Heart Assoc. 2023, 12:e030767. 10.1161\/JAHA.123.030767","journal-title":"J Am Heart Assoc"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.0713","article-title":"Endovascular ultrasound Renal Denervation to treat hypertension: the RADIANCE II randomized clinical trial","volume":"329","author":"Azizi M","year":"2023","unstructured":"Azizi M, Saxena M, Wang Y, et al.. Endovascular ultrasound Renal Denervation to treat hypertension: the RADIANCE II randomized clinical trial. JAMA. 2023, 329:651-61. 10.1001\/jama.2023.0713","journal-title":"JAMA"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1080\/08037051.2020.1828818","article-title":"The randomised Oslo study of renal denervation vs. antihypertensive drug adjustments: efficacy and safety through 7 years of follow-up","volume":"30","author":"Bergland OU","year":"2021","unstructured":"Bergland OU, S\u00f8raas CL, Larstorp AC, et al.. The randomised Oslo study of renal denervation vs. antihypertensive drug adjustments: efficacy and safety through 7 years of follow-up. Blood Press. 2021, 30:41-50. 10.1080\/08037051.2020.1828818","journal-title":"Blood Press"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1038\/s41440-021-00754-7","article-title":"Catheter-based ultrasound renal denervation in patients with resistant hypertension: the randomized, controlled REQUIRE trial","volume":"45","author":"Kario K","year":"2022","unstructured":"Kario K, Yokoi Y, Okamura K, et al.. Catheter-based ultrasound renal denervation in patients with resistant hypertension: the randomized, controlled REQUIRE trial. Hypertens Res. 2022, 45:221-31. 10.1038\/s41440-021-00754-7","journal-title":"Hypertens Res"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1038\/s41440-022-01042-8","article-title":"Long-term reduction in morning and nighttime blood pressure after renal denervation: 36-month results from SPYRAL HTN-ON MED trial","volume":"46","author":"Kario K","year":"2023","unstructured":"Kario K, Mahfoud F, Kandzari DE, et al.. Long-term reduction in morning and nighttime blood pressure after renal denervation: 36-month results from SPYRAL HTN-ON MED trial. Hypertens Res. 2023, 46:280-8. 10.1038\/s41440-022-01042-8","journal-title":"Hypertens Res"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2023.0338","article-title":"Patient-level pooled analysis of ultrasound renal denervation in the sham-controlled RADIANCE II, RADIANCE-HTN SOLO, and RADIANCE-HTN TRIO trials","volume":"8","author":"Kirtane AJ","year":"2023","unstructured":"Kirtane AJ, Sharp AS, Mahfoud F, et al.. Patient-level pooled analysis of ultrasound renal denervation in the sham-controlled RADIANCE II, RADIANCE-HTN SOLO, and RADIANCE-HTN TRIO trials. JAMA Cardiol. 2023, 8:464-73. 10.1001\/jamacardio.2023.0338","journal-title":"JAMA Cardiol"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.4244\/EIJ-D-21-00295","article-title":"Changes in blood pressure after crossover to ultrasound renal denervation in patients initially treated with sham in the RADIANCE-HTN SOLO trial","volume":"17","author":"Mahfoud F","year":"2021","unstructured":"Mahfoud F, Bloch MJ, Azizi M, et al.. Changes in blood pressure after crossover to ultrasound renal denervation in patients initially treated with sham in the RADIANCE-HTN SOLO trial. EuroIntervention. 2021, 17:e1024-32. 10.4244\/EIJ-D-21-00295","journal-title":"EuroIntervention"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.4244\/EIJ-D-22-00305","article-title":"Durability of blood pressure reduction after ultrasound renal denervation: three-year follow-up of the treatment arm of the randomised RADIANCE-HTN SOLO trial","volume":"18","author":"Rader F","year":"2022","unstructured":"Rader F, Kirtane AJ, Wang Y, et al.. Durability of blood pressure reduction after ultrasound renal denervation: three-year follow-up of the treatment arm of the randomised RADIANCE-HTN SOLO trial. EuroIntervention. 2022, 18:e677-85. 10.4244\/EIJ-D-22-00305","journal-title":"EuroIntervention"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.123.22251","article-title":"Impact of antihypertensive medication changes after renal denervation among different patient groups: SPYRAL HTN-ON MED","volume":"81","author":"Townsend RR","year":"2024","unstructured":"Townsend RR, Ferdinand KC, Kandzari DE, et al.. Impact of antihypertensive medication changes after renal denervation among different patient groups: SPYRAL HTN-ON MED. Hypertension. 2024, 81:1095-105. 10.1161\/HYPERTENSIONAHA.123.22251","journal-title":"Hypertension"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000003650","article-title":"Ten-year follow-up of very-high risk hypertensive patients undergoing renal sympathetic denervation","volume":"42","author":"Wang L","year":"2024","unstructured":"Wang L, Li C, Li Z, et al.. Ten-year follow-up of very-high risk hypertensive patients undergoing renal sympathetic denervation. J Hypertens. 2024, 42:801-8. 10.1097\/HJH.0000000000003650","journal-title":"J Hypertens"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-022-02056-5","article-title":"Long-term follow-up of patients undergoing renal sympathetic denervation","volume":"111","author":"Zeijen VJ","year":"2022","unstructured":"Zeijen VJ, Feyz L, Nannan Panday R, et al.. Long-term follow-up of patients undergoing renal sympathetic denervation. Clin Res Cardiol. 2022, 111:1256-68. 10.1007\/s00392-022-02056-5","journal-title":"Clin Res Cardiol"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.120.010075","article-title":"Long-term results up to 12 months after catheter-based alcohol-mediated renal denervation for treatment of resistant hypertension","volume":"14","author":"Mahfoud F","year":"2021","unstructured":"Mahfoud F, Sievert H, Bertog S, et al.. Long-term results up to 12 months after catheter-based alcohol-mediated renal denervation for treatment of resistant hypertension. Circ Cardiovasc Interv. 2021, 14:e010075. 10.1161\/CIRCINTERVENTIONS.120.010075","journal-title":"Circ Cardiovasc Interv"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.122.20853","article-title":"Catheter-based renal denervation: 9-year follow-up data on safety and blood pressure reduction in patients with resistant hypertension","volume":"80","author":"Sesa-Ashton G","year":"2023","unstructured":"Sesa-Ashton G, Nolde JM, Muente I, et al.. Catheter-based renal denervation: 9-year follow-up data on safety and blood pressure reduction in patients with resistant hypertension. Hypertension. 2023, 80:811-9. 10.1161\/HYPERTENSIONAHA.122.20853","journal-title":"Hypertension"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/282695-the-efficacy-of-renal-denervation-in-treating-resistant-hypertension-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T15:12:34Z","timestamp":1723821154000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/282695-the-efficacy-of-renal-denervation-in-treating-resistant-hypertension-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,16]]},"references-count":54,"URL":"https:\/\/doi.org\/10.7759\/cureus.67007","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,16]]}}}